Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine

November 9, 2012 updated by: Monarch Medical Research

A Double-Blind Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine

The objective of this study is to assess the effectiveness and safety of topiramate in the prevention of basilar and hemiplegic migraine in children and adolescents.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The objective of this study is to assess the efficacy and safety of topiramate in the prophylaxis of basilar migraine and hemiplegic migraine in children and adolescents, by comparing two doses, 25 and 100 mg/day.

Study Type

Interventional

Enrollment

40

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Virginia
      • Norfolk, Virginia, United States, 23510
        • Monarch Medical Research - Child and Adolescent Neurology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Must meet International Headache Society (IHS) classification of pediatric migraine with aura: familial hemiplegic migraine (International Classification of Headache Disorders [ICHD] 1.2.4), sporadic hemiplegic migraine (ICHD 1.2.5) or basilar-type migraine (ICHD 1.2.6).
  • Average of 4 migraine-days/month during the 3 months prior to screening.
  • 4 migraine-days during prospective baseline period.
  • At least one of the subject's migraines during the previous 3 months must have been accompanied by their characteristic basilar-type or hemiplegic neurologic symptoms of moderate to severe degree.
  • 6-18 years of age.
  • Weigh more than 25 kg.

  • If female, subjects must:

    1. be premenarchal or otherwise incapable of pregnancy, or
    2. have practiced one of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, spousal/partner sterility, or
    3. be practicing abstinence and agree to continue abstinence or to use an acceptable method of contraception (as listed above) should sexual activity commence.

If (b) or (c), the subject must have a negative urine pregnancy test within one week of study entry.

  • Able to take oral medication in tablet form

  • Willing and able to:

    1. read and comprehend written instructions,
    2. complete the assessment forms,
    3. return for regular visits, and d) adhere to medication regimens.

Exclusion Criteria:

  • Previously failed topiramate therapy for migraine prophylaxis or those who discontinued topiramate due to adverse events.
  • Have taken topiramate within 14 days prior to the start of the prospective baseline period.
  • Have 15 or more headache-days during the prospective baseline period.
  • Have cluster headaches or chronic migraine.
  • Have migraine aura without headache exclusively.
  • Currently have a more painful condition than their migraine pain.
  • Have taken any medications for migraine prophylaxis, within 2 weeks of the start of the prospective baseline period.
  • Progressive neurological disorders or a structural disorder of the brain

  • Overuse analgesic or migraine-specific agents for abortive treatment of migraine:

    • >10 treatment days/month of ergot-containing medication, triptans, or opioids;
    • >15 treatment days/month with simple analgesics (including NSAIDs)
  • Require any injections of corticosteroids or local anesthetics within 60 days of visit 1 or botulinum toxin within 120 days prior to Visit 1.
  • Have previously failed more than 2 adequate trials of an established prophylactic anti-migraine regimen.
  • Subjects starting non-pharmacologic prophylactic approaches within 1 month prior to Visit 1. Non-pharmacologic prophylactic approaches started at least 1 month prior to Visit 1 should be continued throughout the study.
  • Have taken carbonic anhydrase inhibitors or triamterene within 1 month prior to Visit 1.
  • History of nephrolithiasis.
  • Require continuing treatment with anticonvulsant therapy for a non-migraine condition.
  • Significant major psychiatric disorder (e.g., major depression) or subjects receiving anti-psychotic medication.
  • History of attempted suicide or suicidal tendencies.
  • History of substance abuse.
  • Pregnant or lactating females.
  • Clinically unstable neurological, cardiovascular, gastrointestinal, musculoskeletal, pulmonary or other disease.
  • Active liver disease.
  • AST and/or ALT levels greater than 2 times the upper limit of normal range.
  • Received an investigational drug or used an investigational device within 30 days of study entry.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
The primary efficacy outcome will be the reduction in average monthly migraine-days over the entire double-blind phase relative to the prospective baseline period

Secondary Outcome Measures

Outcome Measure
Reduction in frequency, severity and duration of basilar or hemiplegic aura symptoms
Reduction in migraine pain severity and duration
Reduction in migraine episode and headache episode frequency
Reduction in total headache days
Proportion of responders (i.e., the proportion of subjects who experience a ≥ 50% reduction in migraine-days and migraine episodes)
Cumulative reduction in frequency of migraine days and migraine episodes
Reduction in the use of acute/abortive medications
Reduction in migraine-associated symptoms

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Monarch Medical Research

Collaborators

Ortho-McNeil Neurologics, Inc.

Investigators

  • Principal Investigator: Donald W Lewis, MD, Monarch Medical Research

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2004

Study Completion

August 1, 2006

Study Registration Dates

First Submitted

August 15, 2005

First Submitted That Met QC Criteria

August 17, 2005

First Posted (Estimate)

August 18, 2005

Study Record Updates

Last Update Posted (Estimate)

November 12, 2012

Last Update Submitted That Met QC Criteria

November 9, 2012

Last Verified

November 1, 2006

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CAPSS 271

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Basilar Migraine

Clinical Trials on Topiramate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe